For many people with kidney transplants, managing high cholesterol is a daily battle. High levels of LDL cholesterol can damage the new kidney just like it would any other organ. This study asked if a specific injection could help lower those levels without causing problems. Researchers followed 81 patients who had recently received a kidney transplant at three different hospitals in Boston, Massachusetts. They watched them for over two years to see how their cholesterol changed and if any side effects appeared. The team did not report any serious safety issues or reasons for patients to stop taking the medicine during this time. However, the study did not tell us exactly how much the cholesterol dropped for everyone. The main goal was simply to check if the drug was safe to use in this specific population. Because the study was small and focused only on kidney recipients, we cannot yet say for sure if it works better than other options. More research is needed to confirm these early findings before doctors can confidently suggest this treatment to everyone.
Can a new cholesterol drug help kidney transplant patients without causing harm?
Photo by Annie Spratt / Unsplash
What this means for you:
This early study suggests the drug may be safe for kidney transplant patients, but more research is needed. More on Hyperlipidemia
Cerivastatin best for total cholesterol, simvastatin for LDL-C in DKD with hyperlipidemia Lipid-Lowering Drugs Show Different Benefits for Kidney Disease
Frontiers · May 29, 2026
Narrative review on PCSK9 inhibitors for familial hypercholesterolemia Review explores PCSK9 inhibitors for familial hypercholesterolemia
Frontiers · May 27, 2026
Case report and review of literature on acute NSTEMI after fluorescein angiography in a 76-year-old woman Rare heart attack possible after fluorescein angiography in older adults with heart disease
Frontiers · May 18, 2026
FDA Approves Crestor (rosuvastatin) for Cardiovascular Risk Reduction in Adults FDA approves Crestor to prevent heart attacks and strokes in certain adults.
FDA · May 5, 2026